No Result
View All Result
SUBMIT YOUR ARTICLES
  • Login
Thursday, October 2, 2025
TheAdviserMagazine.com
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
No Result
View All Result
TheAdviserMagazine.com
No Result
View All Result
Home Market Research Business

Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say

by TheAdviserMagazine
12 hours ago
in Business
Reading Time: 3 mins read
A A
Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say
Share on FacebookShare on TwitterShare on LInkedIn


Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs should be the first medicines doctors reach for to treat obesity and its complications, a major European medical association advised on Thursday.

Semaglutide, the active ingredient in Novo’s Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European Association for the Study of Obesity published in Nature Medicine.

When a lesser degree of weight loss is required, other medications can be considered, including liraglutide, an older, less effective drug from the same class, naltrexone-bupropion, and phentermine-topiramate, the guideline says. The EASO guidelines are non-binding on individual countries.

Semaglutide, tirzepatide, and other drugs from the class known as GLP-1 agonists are completely transforming care of obesity and its complications, coauthor Dr. Andreea Ciudin of Vall d’Hebron University Hospital in Barcelona said in a statement.

Live Events

Although no treatment algorithm can replace the nuanced clinical judgment necessary for comprehensive patient care, the new guidelines can serve to support therapeutic decision-making in obesity, she said.

SPECIFIC DRUGS FOR SPECIFIC CONDITIONS

The guideline authors analyzed previous clinical trial results, evaluating the impact of medications on weight loss, their safety profile, and their effectiveness in the presence of specific complications. For patients with the physical consequences of too much fatty, or adipose, tissue, tirzepatide should be considered as the first-line treatment for addressing obstructive sleep apnea, and semaglutide for those with knee osteoarthritis, the authors determined.

For patients with conditions linked with obesity-related metabolic and immune dysfunction, they recommend semaglutide as a first choice for those with a history of heart disease or stroke, tirzepatide for individuals with non-alcoholic fatty liver disease, and either tirzepatide or semaglutide for those with prediabetes or type 2 diabetes.

The class of drugs was originally developed to treat type 2 diabetes.

While the drugs are expensive and economic considerations are complex, the cost of not treating obesity at early stages, “thus enabling the progression to complications and end-organ damage, should be weighed equally in health policy and clinical decision-making,” the guideline authors wrote.

The management of obesity should not be limited to weight loss and its complications but should focus on enhanced mental well-being, physical fitness, social functioning, and overall health and quality of life as well, they also said.

Most of the newer medications have not been evaluated for the treatment of individual complications, they acknowledge.

Still, the authors say, the weight-loss effects have been strongly associated with improvements in various complications and there is growing potential for them to positively influence a broader range of disorders such as chronic kidney disease, neurodegenerative diseases, polycystic ovary syndrome, certain cancers, and mental health conditions.

“Given the rapid advances in the field of medications to treat obesity, EASO intends to update the present treatment algorithm regularly to incorporate the latest available evidence,” society President Professor Volkan Yumuk of Istanbul University-Cerrahpaşa said in a statement.

The American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society jointly advised in June that GLP-1 treatment must be accompanied by nutritional and lifestyle strategies.

“Although GLP‐1s alone can produce significant weight reduction and related health benefits, several challenges limit its long‐term success for individuals and populations,” including gastrointestinal side effects, risk of nutrient inadequacies, muscle and bone loss, high costs, frequent discontinuation, and weight regain,” the advisory said.

Add ET Logo as a Reliable and Trusted News Source



Source link

Tags: doctorsdrugsEuropeanLillyNovoobesityoptionTreatmentsWeightLoss
ShareTweetShare
Previous Post

What CEOs are saying about the government shutdown

Next Post

PepsiCo’s new challenge: Making its chips and sodas colorful without artificial dyes

Related Posts

edit post
The NFL is launching professional flag football leagues for both men and women, Commissioner Roger Goodell says

The NFL is launching professional flag football leagues for both men and women, Commissioner Roger Goodell says

by TheAdviserMagazine
October 2, 2025
0

The NFL is set to launch professional flag football leagues for both men and women within the next couple of...

edit post
Nuclear fusion was always 30 years away—now it’s a matter of when, not if, fusion comes online to power AI

Nuclear fusion was always 30 years away—now it’s a matter of when, not if, fusion comes online to power AI

by TheAdviserMagazine
October 2, 2025
0

The breakthrough scientific moment for fusion power—and the potential for nearly limitless electricity from a so-called star in a jar—came...

edit post
Expert breaks down the 2025 tax changes retirees should know

Expert breaks down the 2025 tax changes retirees should know

by TheAdviserMagazine
October 2, 2025
0

Listen and subscribe to Decoding Retirement on Apple Podcasts, Spotify, or wherever you find your favorite podcasts. Retirees face a...

edit post
Biden’s Florida legacy: An economic boom, a magnet for immigrants and a solidly conservative red state

Biden’s Florida legacy: An economic boom, a magnet for immigrants and a solidly conservative red state

by TheAdviserMagazine
October 2, 2025
0

After Paola Freites was allowed into the U.S. in 2024, she and her husband settled in Florida, drawn by warm...

edit post
Market trading guide: Buy Hindustan Zinc, Fortis Health and 2 more stocks for up to 9% gains – Stock Ideas

Market trading guide: Buy Hindustan Zinc, Fortis Health and 2 more stocks for up to 9% gains – Stock Ideas

by TheAdviserMagazine
October 2, 2025
0

India’s benchmark indices, the Nifty and Sensex, ended their eight-day losing streak, led by private banks, auto, and IT stocks....

edit post
Axis Securities gives Nifty target of 25,500, names Bharti Airtel and Lupin among top 15 picks

Axis Securities gives Nifty target of 25,500, names Bharti Airtel and Lupin among top 15 picks

by TheAdviserMagazine
October 2, 2025
0

Among small caps, Mahanagar Gas Ltd (MGL), Kirloskar Brothers, Sansera Engineering, and Kalpataru Projects International are Axis Securities’ top picks.The...

Next Post
edit post
PepsiCo’s new challenge: Making its chips and sodas colorful without artificial dyes

PepsiCo's new challenge: Making its chips and sodas colorful without artificial dyes

edit post
Axis Securities gives Nifty target of 25,500, names Bharti Airtel and Lupin among top 15 picks

Axis Securities gives Nifty target of 25,500, names Bharti Airtel and Lupin among top 15 picks

  • Trending
  • Comments
  • Latest
edit post
What Happens If a Spouse Dies Without a Will in North Carolina?

What Happens If a Spouse Dies Without a Will in North Carolina?

September 14, 2025
edit post
California May Reimplement Mask Mandates

California May Reimplement Mask Mandates

September 5, 2025
edit post
Does a Will Need to Be Notarized in North Carolina?

Does a Will Need to Be Notarized in North Carolina?

September 8, 2025
edit post
Who Needs a Trust Instead of a Will in North Carolina?

Who Needs a Trust Instead of a Will in North Carolina?

September 1, 2025
edit post
DACA recipients no longer eligible for Marketplace health insurance and subsidies

DACA recipients no longer eligible for Marketplace health insurance and subsidies

September 11, 2025
edit post
‘Quiet luxury’ is coming for the housing market, The Corcoran Group CEO says. It’s not just the Hamptons, Aspen, and Miami anymore

‘Quiet luxury’ is coming for the housing market, The Corcoran Group CEO says. It’s not just the Hamptons, Aspen, and Miami anymore

September 9, 2025
edit post
Market Talk – October 2, 2025

Market Talk – October 2, 2025

0
edit post
Dogecoin Consolidates After Recent Rejection, But alt=

Dogecoin Consolidates After Recent Rejection, But $0.32 Retest Looks Inevitable

0
edit post
Why Search For Property Owners First? Here’s Five Reasons

Why Search For Property Owners First? Here’s Five Reasons

0
edit post
Could bitcoin and crypto be headed for an end-of-year rally?

Could bitcoin and crypto be headed for an end-of-year rally?

0
edit post
Deutsche Bank – DBK: Neuer CFO kommt von Morgan Stanley!

Deutsche Bank – DBK: Neuer CFO kommt von Morgan Stanley!

0
edit post
Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say

Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say

0
edit post
Dogecoin Consolidates After Recent Rejection, But alt=

Dogecoin Consolidates After Recent Rejection, But $0.32 Retest Looks Inevitable

October 2, 2025
edit post
Deutsche Bank – DBK: Neuer CFO kommt von Morgan Stanley!

Deutsche Bank – DBK: Neuer CFO kommt von Morgan Stanley!

October 2, 2025
edit post
Market Talk – October 2, 2025

Market Talk – October 2, 2025

October 2, 2025
edit post
The NFL is launching professional flag football leagues for both men and women, Commissioner Roger Goodell says

The NFL is launching professional flag football leagues for both men and women, Commissioner Roger Goodell says

October 2, 2025
edit post
Why Search For Property Owners First? Here’s Five Reasons

Why Search For Property Owners First? Here’s Five Reasons

October 2, 2025
edit post
Bitcoin ETFs Soar With 6 Million Inflow as Ether ETFs Add  Million

Bitcoin ETFs Soar With $676 Million Inflow as Ether ETFs Add $81 Million

October 2, 2025
The Adviser Magazine

The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.

CATEGORIES

  • 401k Plans
  • Business
  • College
  • Cryptocurrency
  • Economy
  • Estate Plans
  • Financial Planning
  • Investing
  • IRS & Taxes
  • Legal
  • Market Analysis
  • Markets
  • Medicare
  • Money
  • Personal Finance
  • Social Security
  • Startups
  • Stock Market
  • Trading

LATEST UPDATES

  • Dogecoin Consolidates After Recent Rejection, But $0.32 Retest Looks Inevitable
  • Deutsche Bank – DBK: Neuer CFO kommt von Morgan Stanley!
  • Market Talk – October 2, 2025
  • Our Great Privacy Policy
  • Terms of Use, Legal Notices & Disclosures
  • Contact us
  • About Us

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.